3/26
08:19 am
atos
Atossa Genetics (ATOS) had its price target raised by HC Wainwright from $7.00 to $25.00. They now have a "buy" rating on the stock.
High
Report
Atossa Genetics (ATOS) had its price target raised by HC Wainwright from $7.00 to $25.00. They now have a "buy" rating on the stock.
3/26
12:54 am
atos
Atossa Therapeutics GAAP EPS of -$4.04 misses by $0.22 [Seeking Alpha]
High
Report
Atossa Therapeutics GAAP EPS of -$4.04 misses by $0.22 [Seeking Alpha]
3/25
06:10 pm
atos
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]
High
Report
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]
3/25
05:30 pm
atos
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
High
Report
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
3/19
08:00 am
atos
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives
Low
Report
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives
3/12
08:21 am
atos
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference [Yahoo! Finance]
Medium
Report
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference [Yahoo! Finance]
3/12
08:00 am
atos
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference
Low
Report
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference
2/11
08:30 am
atos
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
High
Report
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
2/5
08:30 am
atos
Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program
Medium
Report
Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program
1/23
05:06 am
atos
Atossa Genetics (NASDAQ:ATOS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Atossa Genetics (NASDAQ:ATOS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/21
09:28 am
atos
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 [Yahoo! Finance]
Low
Report
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 [Yahoo! Finance]
1/21
09:05 am
atos
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025
Low
Report
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025
1/16
05:28 pm
atos
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy [Yahoo! Finance]
High
Report
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy [Yahoo! Finance]
1/16
04:40 pm
atos
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy
Medium
Report
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy
1/16
06:47 am
atos
Atossa Therapeutics shares rise after FDA grants orphan drug designation for soft tissue sarcoma [Seeking Alpha]
Low
Report
Atossa Therapeutics shares rise after FDA grants orphan drug designation for soft tissue sarcoma [Seeking Alpha]
1/6
08:37 am
atos
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer [Yahoo! Finance]
Medium
Report
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer [Yahoo! Finance]
1/6
08:15 am
atos
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer
Low
Report
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer